J3M-MC-JZQH
Health & Fitness
Only for iPhone
Free · Designed for iPhone. Not verified for macOS.
iPhone
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants with Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02. This app is specifically intended for participants in the J3M-MC-JZQH study only.
Ratings & Reviews
- This app hasn’t received enough ratings or reviews to display an overview.
This update includes improvements and bug fixes to enhance your experience.
The developer, Medable, Inc., indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy .
Data Linked to You
The following data may be collected and linked to your identity:
- Health & Fitness
- Identifiers
- Usage Data
- Diagnostics
Accessibility
The developer has not yet indicated which accessibility features this app supports. Learn More
Information
- Seller
- Medable, Inc.
- Size
- 105.1 MB
- Category
- Health & Fitness
- Compatibility
Requires iOS 14.0 or later.
- iPhone
Requires iOS 14.0 or later. - iPod touch
Requires iOS 14.0 or later. - Mac
Requires macOS 11.0 or later and a Mac with Apple M1 chip or later. - Apple Vision
Requires visionOS 1.0 or later.
- iPhone
- Languages
English and 61 more
- English, Afrikaans, Arabic, Assamese, Bengali, Bulgarian, Catalan, Cebuano, Croatian, Czech, Danish, Dutch, Estonian, Filipino, Finnish, French, Galician, Georgian, German, Greek, Gujarati, Haitian, Hebrew, Hiligaynon, Hindi, Hungarian, Iloko, Italian, Japanese, Kannada, Korean, Latvian, Lithuanian, Malay, Malayalam, Marathi, Norwegian Bokmål, Oriya, Pedi, Polish, Portuguese, Punjabi, Romanian, Russian, Serbian, Sesotho, Setswana, Simplified Chinese, Slovak, Slovenian, Spanish, Swedish, Tamil, Telugu, Thai, Traditional Chinese, Turkish, Ukrainian, Urdu, Vietnamese, Xhosa, Zulu
- Age Rating
4+
- 4+
- Copyright
- © Medable, Inc.